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achievement, the prevalence of HBV surface antigen (HBsAg) 
carrier in the general population (1–59 years old) of China was 
decreased from 9.75 % in 1992 to 7.18 % in 2006 [1]. Despite 
the reduction in the incidence of HBV infection, there are still 
about 93 million people chronically infected with HBV and an 
estimated 20 million cases of symptomatic chronic hepatitis B 
in China now. Therefore, the healthcare burden from chronic 
HBV infection is still a big challenge for China.
Patients with chronic HBV infection may develop liver 
fibrosis, cirrhosis, hepatic decompensation, and hepatocel-
lular carcinoma (HCC) and eventually die from liver fail-
ure and other complications [2]. Numerous studies have 
shown that active HBV replication leads to liver injury and 
disease progression [3]. As pointed out by the “Guidelines 
for prevention and treatment of chronic hepatitis B” from 
the American Association for the Study of liver disease 
(AASLD), European Association for the Study of the Liver 
(EASL), Asia Pacific Association for the Study of the Liver 
(APASL), and Chinese Association for the Study of liver dis-
ease (CASLD), the ultimate long-term goal of treatment is to 
prevent hepatic decompensation, reduce progression to cir-
rhosis and/or HCC, and prolong survival [4]. The short-term 
goal is to permanently suppress HBV replication. Therefore, 
antiviral therapy plays a central role in controlling chronic 
HBV infection and preventing the disease progression. Due 
to economic and medical system issues, the antiviral treat-
ment in China has its own unique characteristics [5]. In this 
review, we will discuss some key issues in the area of antivi-
ral treatment for chronic hepatitis B in China.
Patients who need antiviral therapy
Patients with positive serum HBsAg for more than 
6 months or patients with positive HBsAg and chronic liver 
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Introduction
There are about 350 million people worldwide suffering from 
chronic hepatitis B virus (HBV) infection. China is one of the 
countries with a high prevalence of HBV infection [1]. The 
HBV vaccination program for all newborns was implemented 
by the Chinese government in 1992, which increased the 
yearly national HBV vaccine inoculation rate. Based on this 
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disease proven by biopsy can be diagnosed with chronic 
HBV infection. Based on the information from the guide-
lines for management of chronic hepatitis B virus infection 
published by CASLD in 2010, the indications for antiviral 
therapy are as follows:
General indications: (1) For HBeAg positive patients 
with serum HBV DNA ≥ 105 copies/mL (equivalent to 
20,000 IU/mL) and for HBeAg negative patients with 
HBV DNA ≥ 104 copies/mL (equivalent to 2,000 IU/mL); 
(2) alanine transaminase (ALT) ≥ 2 upper limit of normal 
(ULN), but for patients treated with interferon-α (IFN-α), 
ALT should be ≤10 ULN and the total bilirubin should be 
<2 ULN;and (3) ALT < 2 ULN, but the liver biopsy shows 
a histological activity index (Knodell HAI) ≥4, or degree 
of necroinflammation ≥G2, or degree of fibrosis ≥S2.
For patients with persistently positive HBV DNA who 
do not show the criteria mentioned above, the antivi-
ral therapy should be applied if they are in the following 
conditions:
1. Patients older than 40 years and ALT > ULN.
2. For patients older than 40 years and ALT is sustained 
normal, a liver biopsy is recommended. If the Knodell 
HAI is ≥4, or the degree of necroinflammation ≥G2, 
or the degree of fibrosis ≥S2, then antiviral therapy 
should be applied.
3. If disease progression is evident, for example, spleen 
enlargement, liver biopsy is recommended, and antivi-
ral therapy should be applied if necessary [1].
As to the standards for determining the patients who 
need antiviral therapy, CASLD has very similar rules as 
AASLD, EASL, or APASL. All these associations recom-
mend that the patients need to be evaluated based on the 
state of persistent HBsAg, HBeAg, the level of HBV DNA, 
and the degree of liver inflammation and fibrosis, and clini-
cians may decide whether the patients are appropriate for 
antiviral therapy. Histology of the liver biopsy provides 
direct evidence for grading the inflammation and staging 
the fibrosis in the liver; however, liver biopsy is hard to per-
form in most hospitals because of the patients’ refraction.
ALT is routinely tested as a biochemical marker to 
reflect the degree of the liver inflammation, it is one of 
the important markers for identifying whether the patient 
in an immune activation stage or not. The ULN for ALT is 
defined as 40U/L in China based on the results of a national 
wide survey in the 1950s [6, 7]. However, increasing evi-
dence from China shows that this reference value cannot 
dependably reflect the degree of the liver inflammation. 
For chronic hepatitis B patients with persistently normal 
ALT, the liver biopsy results showed that 34.4 % of them 
had fibrosis with degree ≥S2 or fibrosis degree ≥S1 and 
inflammation degree ≥G2 [8]. Another study reported that 
in patients with ALT < 0.5 ULN, the proportion with signif-
icant liver inflammation and fibrosis was 16.6 %, whereas 
in patients with ALT between 0.5 and 1 ULN, the propor-
tion increased to 40 % [9]. For patients with ALT between 
1 ULN and 2 ULN, the proportion of fibrosis could be up 
to 61.8 % [8]. These data indicate that the ULN of ALT 
may need to be revised for China.
A large sample survey in Italy showed the ULN of ALT 
should be 30 U/L for healthy men and 19 U/L for healthy 
women [10]. The guidelines of AASLD in 2009 recom-
mended to use these values to evaluate the liver inflamma-
tion status of the patients [11]. A study in Korea showed 
that the ULN of ALT for Koreans was 33 U/L for the 
healthy men and 25 U/L for healthy women [12], and these 
values had been applied in the guidelines for Korea in 2012 
[13]. A large sample survey for ULN of ALT, including 
28,642 healthy men and 24,413 healthy women was per-
formed in China in 2011 and showed the ULN of ALT was 
35 U/for men and 23 U/L for women in Chinese Han popu-
lation [14]. Based on these new findings, CASLD should 
adjust the ULN of ALT reference value in the next ver-
sion of the guidelines. Otherwise, the patients with mildly 
elevated ALT (ALT between 1 ULN and 2 ULN) or per-
sistently normal ALT may not receive the opportunity of 
antiviral therapy.
Drugs available for antiviral therapy in China
Two kinds of antiviral agents have been approved for the 
therapy of chronic hepatitis B: IFN-α and nucleot(s)ide 
analogs. The first includes conventional IFN-α and Peg-
IFN-α, and the second includes lamivudine (LAM), adefo-
vir dipivoxil (ADV), telbivudine (LdT), entecavir (ETV), 
and tenofovir (TFV). All these medicines are now available 
in China. The randomized clinical trials confirmed that Peg-
IFN-α treatment could obtain a higher HBeAg seroconver-
sion rate in a limited period of treatment; ETV and TFV 
have a potent antiviral effect, low incidence of drug resist-
ance, and good safety [11, 15–19]. These drugs are listed 
as the first-line antiviral drugs for chronic hepatitis B treat-
ment by AASLD and EASL. The conventional IFN-α, LdT, 
ADV, and LAM are the second-line antiviral drugs [11, 20]. 
In China, compared with the average yearly incomes of the 
general population, the Peg-IFN-α and ETV produced by 
foreign or Sino-foreign joint venture pharmaceutical com-
panies are very expensive and are only covered by a small 
proportion of medicare payments, or not covered at all. 
Most of Chinese patients with chronic hepatitis B cannot 
afford Peg-IFN-α or ETV, and consequently these drugs are 
rarely used for the initial antiviral treatment. The clinicians 
have to choose from the second-line drugs with affordable 
prices for the patients, especially in rural areas. By using 
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the second-line drugs, the health system reduces the cost 
of treatment in a short term, but the medical expense will 
increase in the long term if the patients develop drug resist-
ance or suboptimal response.
With the development of local pharmaceutical compa-
nies, the generic drugs of conventional IFN-α, LAM, ADV, 
and ETV have been successfully produced and approved 
for the treatment of chronic hepatitis B in China. The appli-
cation of domestic produced Peg-IFN-α in chronic hepatitis 
B is still in clinical trial. The multicenter, large sample clin-
ical studies show that there are no significant differences 
in antiviral efficacy, bioavailability, and safety between 
the domestic IFN-α/nucleot(s)ide analogs and the original 
drugs [21–23]. The price of domestic generic drugs is only 
50–70 % of the original drugs. This provides more choices 
for the clinician in addition to reducing the economic pres-
sure on the patients.
Traditional Chinese medicines (TCM) have been used 
for treating chronic hepatitis B for a long time. Over 90 % 
of chronic hepatitis B patients received the TCM therapy 
[24]. Preclinical and clinical trials, which were performed 
in China, indicated that some traditional Chinese medicine 
preparations, like phyllanthus urinaria, decoction of small 
bupleurum (a medicinal root found natively in East Asia), 
matrine (an alkaloid found in plants from the Sophora 
genus with anticancer activity), or rhubarb, had a potential 
effect on inhibiting HBV replication, regulating the hosts’ 
immune function, and improving liver function [25, 26]. A 
short-term clinical follow-up study found that matrine treat-
ment could result in a similar curative effect as interferon in 
HBeAg seroconversion and HBV DNA reduction [27]. The 
small bupleurum decoction and phyllanthus urinaria prepa-
rations are reported to have a similar therapeutic effect as 
conventional IFN [26, 28]. Although it seems that TCM 
can be used as alternative medicine for antiviral treatment, 
the antiviral effect needs to be evaluated in well-designed 
and randomized clinical trials. In addition, the composition 
of TCM is very complex, and it is difficult to explain the 
mechanism from the standpoint of modern medicine. This 
limits the application of TCM in the treatment of chronic 
hepatitis B [25, 29].
The drug resistance and rescue strategies
Due to the low cost, the second-line nucleot(s)ide ana-
logs (LAM, LdT, and ADV) are widely used in China. 
When the second-line NAs are chosen for long-term 
therapy regimens, drug resistance may occur and cause 
virologic breakthrough, hepatitis flare, and even death. 
Therefore, rescue strategies need to be taken once the 
resistant strains of HBV are detected. For the LAM-
resistant strain, the therapy can switch to monotherapy 
with either Adefovir or Entecavir, add-on ADV to LAM 
or use a combination treatment of ADV and ETV. The 
experience from China is that ETV + ADV is superior 
to LAM + ADV, and LAM + ADV is better than mon-
otherapy [30, 31]. However, due to the risk of frequent 
resistance development against ETV with LAM-resist-
ant strains, further research is needed to assess long-
term cost-effectiveness of ETV combination treatment 
to LAM-resistant disease. For the ADV-resistant strains, 
adding LAM, or LdT, or ETV to ADV is recommended 
[1]. Current research shows that both LdT + ADV com-
bination therapy and ETV monotherapy leads to signifi-
cant decreases in serum HBV DNA in the patients with 
resistance to ADV, and LdT + ADV combination therapy 
exhibits a significantly higher rate of HBeAg seroconver-
sion than ETV monotherapy [32]. For the patients with 
resistance to LdT or ETV, adding ADV is recommended, 
but its antiviral efficacy and safety are not established 
[1]. A small sample survey showed that LdT + ADV 
combination therapy led to significant decreases in serum 
HBV DNA levels, normalization of ALT, and increased 
the rate of HBeAg seroconversion in patients with resist-
ance to LdT [33].
Response guided therapy
The serum HBV DNA levels, serum ALT levels, HBV 
genotype, HBeAg status, and other factors in patients with 
initial antiviral treatment are important factors for pre-
dicting the response to antiviral therapy which has been 
called baseline guided therapy (BGT). In recent years, the 
response of patients to treatment during antiviral treat-
ment as the guidance (response guided therapy, RGT) 
has become the focus of attention. A multicenter study on 
optimization of telbivudine (LdT) treatment led by Hou 
in China is based on the idea of RGT. Chronic hepatitis B 
patients were evaluated after 24 weeks of LdT monother-
apy. If the serum level of HBV DNA was ≥300 copies/mL, 
patients were switched to LdT plus ADV combination ther-
apy. Otherwise, patients would maintain LdT monotherapy. 
After 105 weeks of treatment, the rates of HBV DNA < 300 
copies/mL in the LdT plus ADV group and the LdT group 
were not significantly different (76.7 vs. 61.2 %). However, 
the rates of viral mutations and drug resistance were signif-
icantly different between these two groups (6.0 vs. 30.4 %, 
2.7 vs. 25.8 %) [34].
Combination therapy
Combination antiviral therapy strategy has been used for 
rescue therapy and RGT. It is uncertain whether it should 
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be used for initial treatment. Some studies indicated that 
initial combination antiviral treatment can improve efficacy 
and reduce the rates of viral mutations in HBeAg posi-
tive CHB patients with high viral load (≥108 IU/mL) and 
in decompensated cirrhosis patients who need long-term 
NAs antiviral therapy [35, 36]. The combination of IFN-α 
and NA or two NAs are the mainstream strategy for com-
bination treatment. Although there are some reports from 
China showed that combination treatment was significantly 
superior to monotherapy (see Table 1) [37]. However, the 
CASLD does not recommend the initial LAM-ADV com-
bination therapy for CHB patients.
TCM are also candidates for combination therapy. The 
combination of matrine and nucleot(s)ide analogs, such 
as LAM, has synergistic effect and can achieve even bet-
ter therapeutic effects for inhibiting HBV replication. They 
can restore liver function quickly and reduce the incidence 
of virus bounce after withdrawal of the nucleot(s)ide ana-
logs [25, 27]. But it need further study to confirm.
Prospective
It is clear that many chronic HBV patients have benefited 
from antiviral treatment. The incidence of liver fibrosis, 
cirrhosis, hepatic decompensation, and HCC has been 
reduced. However, the clinicians have new challenges 
to face. In the US and European countries, primary non-
response and suboptimal response is rare in patients who 
received TDF and ETV treatment, but may occur due 
to pharmaceutical response of the host to the drugs. In 
China, poor adherence of patients to treatment, relative 
high costs of the first-line antiviral drugs and resistance 
development may be the key factors that cause the non-
response, suboptimal response, and even treatment fail-
ure. Since 2008, several large cohort studies supported by 
the government have been carried out on the optimizing 
strategy for the treatment of chronic hepatitis B in China. 
This may serve as one of the important ways to solve this 
problem and to benefit most of the patients. In addition, 
recent studies show that the agonist of Toll-like recep-
tor 7 and HBsAg/HBsAb immune complex can induce 
prolonged suppression of hepatitis B virus in chroni-
cally infected individules by stimulating the innate and 
acquired immune response. Therefore, the immune modu-
lation therapy may be a new strategy for antiviral treat-
ment on chronic hepatitis B.
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